"Our presentions today demonstrate that full dose pacritinib achieved higher response rates and a similar, manageable safety profile compared to lower-dose ruxolitinib in patients with myelofibrosis who have moderate or severe thrombocytopenia," said Adam Craig, President and Chief Executive Officer of CTI BioPharma. "As the commercial launch of VONJOTM (pacritinib) in the U.S. continues to exceed our expectations, we are pleased to highlight VONJO's clinical value as a potential best in class treatment for patients with cytopenic myelofibrosis with platelet counts below 50 × 109/L."
Presentation materials will be available at ctibiopharma.com.
https://finance.yahoo.com/news/cti-biopharma-presents-pivotal-data-110000319.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.